Aerie reports Q2 cash, equivalents and investments of $56.6 million

Aerie Pharmaceuticals reported second-quarter cash, cash equivalents and investments of $56.6 million, according to a company press release.

The net loss attributable to common stockholders was $11.8 million, or $0.49 per share, compared with $6.5 million and $6.59 per share during the same period last year, when the company was still privately held, according to the press release.

Aerie also reported the weighted average number of common stock shares outstanding that contributed to the net loss per common share were 23,893,651 for Q2 of 2014, and 981,644 for 2013. However, an increase in this area was due to the capital structure associated with the initial public offering in October 2013.

The company’s clinical and non-clinical preparatory activities for Rhopressa and Roclatan led to higher operating expenses in Q2 in 2014 compared with 2013; increased research and development and growth were a result of Aerie becoming a public company in October 2013, according to the press release.